Investigational Drug Information for QPI-1002
✉ Email this page to a colleague
What is the drug development status for QPI-1002?
QPI-1002 is an investigational drug.
There have been 8 clinical trials for QPI-1002.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2016.
The most common disease conditions in clinical trials are Ischemia, Delayed Graft Function, and Wounds and Injuries. The leading clinical trial sponsors are Quark Pharmaceuticals and [disabled in preview].
There are two US patents protecting this investigational drug and twenty-one international patents.
Summary for QPI-1002
| US Patents | 2 |
| International Patents | 21 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2016-03-01) |
| Vendors | 0 |
Recent Clinical Trials for QPI-1002
| Title | Sponsor | Phase |
|---|---|---|
| QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery | Quark Pharmaceuticals | Phase 3 |
| QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant | Quark Pharmaceuticals | Phase 3 |
| Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) | Quark Pharmaceuticals | Phase 2/Phase 3 |
Clinical Trial Summary for QPI-1002
Top disease conditions for QPI-1002
Top clinical trial sponsors for QPI-1002
US Patents for QPI-1002
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| QPI-1002 | ⤷ Try a Trial | Soluble C5aR antagonists | ChemoCentryx, Inc. (Mountain View, CA) | ⤷ Try a Trial |
| QPI-1002 | ⤷ Try a Trial | Soluble C5aR antagonists | ChemoCentryx, Inc. (Mountain View, CA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for QPI-1002
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| QPI-1002 | Argentina | AR108097 | 2036-04-04 | ⤷ Try a Trial |
| QPI-1002 | Australia | AU2017246228 | 2036-04-04 | ⤷ Try a Trial |
| QPI-1002 | Brazil | BR112018070214 | 2036-04-04 | ⤷ Try a Trial |
| QPI-1002 | Canada | CA3019137 | 2036-04-04 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
